Durotimi Damilola Ayodeji

Durotimi Ayodeji practices at TidalHealth Peninsula Regional in Salisbury, Maryland, part of TidalHealth Peninsula Regional.

Durotimi Ayodeji's NPI, 1316391204, was assigned on April 18, 2016. Durotimi Ayodeji holds Maryland license D0087503.

Durotimi Ayodeji's primary practice is TidalHealth Peninsula Regional, at 100 East Carroll Avenue, Salisbury, MD 21801 in Wicomico County. The practice phone is (410) 546-6400.

Durotimi Ayodeji's primary practice is TidalHealth Peninsula Regional in Salisbury, Maryland, part of TidalHealth Peninsula Regional. Durotimi Ayodeji is also affiliated with TidalHealth Atlantic. The medical group on file is TidalHealth Cardiovascular Surgery. Dmand AI also links Durotimi Ayodeji to 1 more community health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Durotimi Ayodeji practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Durotimi Ayodeji's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Durotimi Ayodeji is licensed in Maryland.

CMS data shows 1,054 Medicare services from Durotimi Ayodeji across 4 procedure codes in 2024, for 371 Medicare patients. Medicare paid $80,922 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 371 Medicare patients who saw Durotimi Ayodeji in 2024. The largest group is 75 to 84, with 126 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Durotimi Ayodeji's median patient age at 66, with 50% women.

In 2024, Durotimi Ayodeji wrote 235 Medicare Part D claims for 128 patients. 88% of them were for generic drugs. CMS names the drug for 60 of them, across 4 drugs with 11 or more claims each, at $263 in total drug cost. In 2023, CMS named 83 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Durotimi Ayodeji for performance year 2024, reported as part of a group. Durotimi Ayodeji accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 124 general payments to Durotimi Ayodeji from 20 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $530.